Filter News

Watson Pharmaceuticals, Inc. Launches TriNessa(TM) Oral Contraceptive

Published: Dec 30, 2003

CORONA, Calif., Dec. 29 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that it has initiated shipments of TriNessa(TM) (norgestimate and ethinyl estradiol tablets), the authorized brand equivalent of the oral contraceptive Ortho Tri-Cyclen(R), marketed by Ortho-McNeil Pharmaceutical, Inc. TriNessa(TM) is indicated for the prevention of pregnancy in women and for the treatment of moderate acne vulgaris in females greater than or equal to 15 years of age who have no known contraindications to oral contraceptive therapy, desire contraception, have achieved menarche, and are unresponsive to topical anti-acne medications. For the 12-months ending October 2003, Ortho Tri-Cyclen(R) had sales of approximately $715 million, according to IMS Health data.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO )

"The launch of TriNessa(TM) represents our fifth and largest oral contraceptive launch in 2003," said Joseph Papa, Watson's President and Chief Operating Officer. "This launch extends Watson's industry leading oral contraceptive portfolio to 16 products and 24 strengths."

Watson has launched TriNessa(TM) as part of a supply agreement with OMJ Pharmaceuticals, Inc., an affiliate of Ortho-McNeil.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc., headquartered in Corona, California, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes branded and generic pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.

For press releases and other company information, visit Watson Pharmaceuticals' Web site at http://www.watsonpharm.com/ .

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts about Watson are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. These forward-looking statements involve risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, risks and uncertainties detailed in Watson's most recent filings with the Securities and Exchange Commission, including Watson's Annual Report on Form 10-K for the year ended December 31, 2002 and its Quarterly Report on Form 10-Q for the quarters ended March 31, June 30, and September 30, 2003.

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, photodesk@prnewswire.comWatson Pharmaceuticals, Inc.

CONTACT: Patty Eisenhaur (Investors), +1-909-493-5611, or Chris Eso(Media), +1-909-493-4013, both Watson Pharmaceuticals, Inc.

Back to news